Pilot study of CYP2B6 genetic variation to explore the contribution of nitrosamine activation to lung carcinogenesis

International Journal of Molecular Sciences

Volumn 14, Issue 4, 2013, Pages 8381-8392

  Wassenaar, Catherine A ^a   Dong, Qiong ^b   Amos, Christopher I ^c   Spitz, Margaret R ^d   Tyndale, Rachel F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

CHRNA5 CHRNA3 CHRNB4; CYP2A6; CYP2B6; Genetic variation; Lung cancer risk; Tobacco specific nitrosamines

Indexed keywords

CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; NITROSAMINE; CHRNA5 PROTEIN, HUMAN; CHRNB4 PROTEIN, HUMAN; CYP2A6 PROTEIN, HUMAN; CYP2B6 PROTEIN, HUMAN; NERVE PROTEIN; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR SUBUNIT ALPHA3;

ADULT; ARTICLE; CANCER RISK; CHRNA3 GENE; CHRNA5 GENE; CHRNB4 GENE; CONTROLLED STUDY; CYP2A6 GENE; CYP2B6 GENE; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HIGH RISK POPULATION; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; ONCOGENE; RISK ASSESSMENT; RISK FACTOR; AGED; FEASIBILITY STUDY; GENETIC VARIATION; GENETICS; GENOTYPE; LUNG NEOPLASMS; METABOLIC ACTIVATION; METABOLISM; MIDDLE AGED; ODDS RATIO; PILOT STUDY;

NICOTIANA TABACUM;

ACTIVATION, METABOLIC; AGED; CYTOCHROME P-450 CYP2A6; CYTOCHROME P-450 CYP2B6; FEASIBILITY STUDIES; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NITROSAMINES; ODDS RATIO; PILOT PROJECTS; RECEPTORS, NICOTINIC; RISK FACTORS;

EID: 84877028732     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14048381     Document Type: Article

References (43)

1. Wassenaar, C.A.; Dong, Q.; Wei, Q.; Amos, C.I.; Spitz, M.R.; Tyndale, R.F. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J. Natl. Cancer Inst. 2011, 103, 1342-1346.
2. Rossini, A.; de Almeida Simao, T.; Albano, R.M.; Pinto, L.F. CYP2A6 polymorphisms and risk for tobacco-related cancers. Pharmacogenomics 2008, 9, 1737-1752.
3. Schuller, H.M. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat. Rev. Cancer 2009, 9, 195-205.
4. Gervot, L.; Rochat, B.; Gautier, J.C.; Bohnenstengel, F.; Kroemer, H.; de Berardinis, V.; Martin, H.; Beaune, P.; de Waziers, I. Human CYP2B6: Expression, inducibility and catalytic activities. Pharmacogenetics 1999, 9, 295-306.
5. Anttila, S.; Raunio, H.; Hakkola, J. Cytochrome P450-mediated pulmonary metabolism of carcinogens: Regulation and cross-talk in lung carcinogenesis. Am. J. Respir. Cell Mol. Biol. 2011, 44, 583-590.
6. Jalas, J.R.; Hecht, S.S.; Murphy, S.E. Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem. Res. Toxicol. 2005, 18, 95-110.
7. Weng, Y.; Fang, C.; Turesky, R.J.; Behr, M.; Kaminsky, L.S.; Ding, X. Determination of the role of target tissue metabolism in lung carcinogenesis using conditional cytochrome P450 reductase-null mice. Cancer Res. 2007, 67, 7825-7832.
8. Dicke, K.E.; Skrlin, S.M.; Murphy, S.E. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug. Metab. Dispos. 2005, 33, 1760-1764.
9. Wong, H.L.; Murphy, S.E.; Hecht, S.S. Cytochrome P450 2A-catalyzed metabolic activation of structurally similar carcinogenic nitrosamines: N'-nitrosonornicotine enantiomers, N-nitrosopiperidine, and N-nitrosopyrrolidine. Chem. Res. Toxicol. 2005, 18, 61-69.
10. Lee, A.M.; Jepson, C.; Shields, P.G.; Benowitz, N.; Lerman, C.; Tyndale, R.F. CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. Cancer Epidemiol. Biomark. Prev. 2007, 16, 1312-1314.
11. Al Koudsi, N.; Tyndale, R.F. Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. Xenobiotica 2010, 40, 381-392.
12. Haberl, M.; Anwald, B.; Klein, K.; Weil, R.; Fuss, C.; Gepdiremen, A.; Zanger, U.M.; Meyer, U.A.; Wojnowski, L. Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet. Genomics 2005, 15, 609-624.
13. Hoffman, S.M.; Nelson, D.R.; Keeney, D.S. Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 2001, 11, 687-698.
14. Johnstone, E.; Benowitz, N.; Cargill, A.; Jacob, R.; Hinks, L.; Day, I.; Murphy, M.; Walton, R. Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin. Pharmacol. Ther. 2006, 80, 319-330.
15. Zanger, U.M.; Klein, K.; Saussele, T.; Blievernicht, J.; Hofmann, M.H.; Schwab, M. Polymorphic CYP2B6: Molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007, 8, 743-759.
16. Lee, A.M.; Jepson, C.; Hoffmann, E.; Epstein, L.; Hawk, L.W.; Lerman, C.; Tyndale, R.F. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol. Psychiatr. 2007, 62, 635-641.
17. Xu, C.; Ogburn, E.T.; Guo, Y.; Desta, Z. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: Implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. Drug Metab. Dispos. 2012, 40, 717-725.
18. Yimer, G.; Amogne, W.; Habtewold, A.; Makonnen, E.; Ueda, N.; Suda, A.; Worku, A.; Haefeli, W.E.; Burhenne, J.; Aderaye, G.; et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: A prospective cohort study. Pharmacogenomics J. 2011, 12, 499-506.
19. Rotger, M.; Tegude, H.; Colombo, S.; Cavassini, M.; Furrer, H.; Decosterd, L.; Blievernicht, J.; Saussele, T.; Gunthard, H.F.; Schwab, M.; et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther. 2007, 81, 557-566.
20. Desta, Z.; Saussele, T.; Ward, B.; Blievernicht, J.; Li, L.; Klein, K.; Flockhart, D.A.; Zanger, U.M. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 2007, 8, 547-558.
21. Barrett, J.C.; Fry, B.; Maller, J.; Daly, M.J. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21, 263-265.
22. Larsen, J.E.; Colosimo, M.L.; Yang, I.A.; Bowman, R.; Zimmerman, P.V.; Fong, K.M. CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung. Carcinogenesis 2006, 27, 525-532.
23. Alexandrie, A.K.; Nyberg, F.; Warholm, M.; Rannug, A. Influence of CYP1A1, GSTM1, GSTT1, and NQO1 genotypes and cumulative smoking dose on lung cancer risk in a Swedish population. Cancer Epidemiol. Biomark. Prev. 2004, 13, 908-914.
24. Ishibe, N.; Wiencke, J.K.; Zuo, Z.F.; McMillan, A.; Spitz, M.; Kelsey, K.T. Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans. Cancer Epidemiol. Biomark. Prev. 1997, 6, 1075-1080.
25. Schabath, M.B.; Spitz, M.R.; Hong, W.K.; Delclos, G.L.; Reynolds, W.F.; Gunn, G.B.; Whitehead, L.W.; Wu, X. A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer 2002, 37, 35-40.
26. Schwartz, A.G.; Prysak, G.M.; Bock, C.H.; Cote, M.L. The molecular epidemiology of lung cancer. Carcinogenesis 2007, 28, 507-518.
27. King, B.; Dube, S.; Kaufmann, R.; Shaw, L.; Pechacek, T. Vital signs: Current cigarette smoking among adults aged ≥18 years-United States, 2005-2010. Morb. Mortal. Wkly. Rep. 2011, 60, 1207-1212.
28. Lips, E.H.; Gaborieau, V.; McKay, J.D.; Chabrier, A.; Hung, R.J.; Boffetta, P.; Hashibe, M.; Zaridze, D.; Szeszenia-Dabrowska, N.; Lissowska, J.; et al. Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17,000 individuals. Int. J. Epidemiol. 2010, 39, 563-577.
29. Sellers, E.M.; Ramamoorthy, Y.; Zeman, M.V.; Djordjevic, M.V.; Tyndale, R.F. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicotine Tob. Res. 2003, 5, 891-899.
30. Takeuchi, H.; Saoo, K.; Yokohira, M.; Ikeda, M.; Maeta, H.; Miyazaki, M.; Yamazaki, H.; Kamataki, T.; Imaida, K. Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice. Cancer Res. 2003, 63, 7581-7583.
31. Bao, Z.; He, X.Y.; Ding, X.; Prabhu, S.; Hong, J.Y. Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab. Dispos. 2005, 33, 258-261.
32. Ding, X.; Kaminsky, L.S. Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 2003, 43, 149-173.
33. Cauffiez, C.; Lo-Guidice, J.M.; Quaranta, S.; Allorge, D.; Chevalier, D.; Cenee, S.; Hamdan, R.; Lhermitte, M.; Lafitte, J.J.; Libersa, C.; et al. Genetic polymorphism of the human cytochrome CYP2A13 in a French population: Implication in lung cancer susceptibility. Biochem. Biophys. Res. Commun. 2004, 317, 662-669.
34. Wang, H.; Tan, W.; Hao, B.; Miao, X.; Zhou, G.; He, F.; Lin, D. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res. 2003, 63, 8057-8061.
35. Binnington, M.J.; Zhu, A.Z.; Renner, C.C.; Lanier, A.P.; Hatsukami, D.K.; Benowitz, N.L.; Tyndale, R.F. CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. Pharmacogenet Genomics 2012, 22, 429-440.
36. Boles, M.; Rohde, K.; He, H.; Maher, J.E.; Stark, M.J.; Fenaughty, A.; O'Connor, T. Effectiveness of a tobacco quitline in an indigenous population: A comparison between Alaska Native people and other first-time quitline callers who set a quit date. Int. J. Circumpolar Health 2009, 68, 170-181.
37. Fu, S.S.; Kodl, M.M.; Joseph, A.M.; Hatsukami, D.K.; Johnson, E.O.; Breslau, N.; Wu, B.; Bierut, L. Racial/Ethnic disparities in the use of nicotine replacement therapy and quit ratios in lifetime smokers ages 25 to 44 years. Cancer Epidemiol. Biomark. Prev. 2008, 17, 1640-1647.
38. Murray, R.P.; Connett, J.E.; Buist, A.S.; Gerald, L.B.; Eichenhorn, M.S. Experience of Black participants in the Lung Health Study smoking cessation intervention program. Nicotine Tob. Res. 2001, 3, 375-382.
39. Smith, J.J.; Ferucci, E.D.; Dillard, D.A.; Lanier, A.P. Tobacco use among Alaska Native people in the EARTH study. Nicotine Tob Res. 2010, 12, 839-844.
40. Lanier, A.P.; Kelly, J.J.; Maxwell, J.; McEvoy, T.; Homan, C. Cancer in Alaska Native people, 1969-2003. Alaska Med. 2006, 48, 30-59.
41. Haiman, C.A.; Stram, D.O.; Wilkens, L.R.; Pike, M.C.; Kolonel, L.N.; Henderson, B.E.; Le Marchand, L. Ethnic and racial differences in the smoking-related risk of lung cancer. N. Engl. J. Med. 2006, 354, 333-342.
42. Hofmann, M.H.; Blievernicht, J.K.; Klein, K.; Saussele, T.; Schaeffeler, E.; Schwab, M.; Zanger, U.M. Aberrant splicing caused by single nucleotide polymorphism c.516 G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J. Pharmacol. Exp. Ther. 2008, 325, 284-292.
43. Saccone, N.L.; Culverhouse, R.C.; Schwantes-An, T.H.; Cannon, D.S.; Chen, X.; Cichon, S.; Giegling, I.; Han, S.; Han, Y.; Keskitalo-Vuokko, K.; et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: A meta-analysis and comparison with lung cancer and COPD. PLoS Genet. 2010, 6, e1001053.